Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 5/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 4/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | PTGES | O14684 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | PDE5A | O76074 | 1/20 | 0.43 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30267663 | 1.00 | CYP19A1 (0.58) | CYP19A1KMT2APTGS2MEN1PTGS1 | |
| SCHEMBL7177937 | 0.88 | KMT2A (0.45) | CYP19A1KMT2APTGS2MEN1PTGS1 | |
| SCHEMBL3296865 | 0.87 | CYP19A1 (0.60) | CYP19A1KMT2APTGS2MEN1PTGS1 | |
| Rofecoxib SCHEMBL5302652 | 0.82 | PTGS2 (0.53) | CYP19A1KMT2APTGS2MEN1PTGS1 | |
| SCHEMBL4799474 | 0.75 | SMN1; SMN2 (0.39) | CYP19A1KMT2APTGS2MEN1PTGS1 | |
| SCHEMBL9617997 | 0.75 | CYP19A1 (0.66) | CYP19A1KMT2APTGS2MEN1PTGS1 | |
| SCHEMBL4869129 | 0.74 | KMT2A (0.46) | CYP19A1KMT2APTGS2MEN1PTGS1 | |
| SCHEMBL4367865 | 0.74 | ALDH1A1 (0.53) | CYP19A1KMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL9550836 | 0.74 | CYP19A1 (0.65) | CYP19A1KMT2APTGS2MEN1PTGS1 | |
| SCHEMBL8979118 | 0.74 | CYP19A1 (0.65) | CYP19A1KMT2APTGS2MEN1PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 402 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210346328-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS | THE JOHNS HOPKINS UNIVERSITY | 2021-11-11 | — | — | US | claimed |
| WO-2020061475-A2 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-03-26 | — | — | WO | claimed |
| US-9833433-B1 | Compositions, methods of use, and methods of treatment | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2017-12-05 | — | — | US | claimed |
| US-20170340600-A1 | COMPOSITIONS, METHODS OF USE, AND METHODS OF TREATMENT | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-11-30 | — | — | US | claimed |
| US-9763912-B2 | Compositions, methods of use, and methods of treatment | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2017-09-19 | — | — | US | claimed |
| US-20160250178-A1 | COMPOSITIONS, METHODS OF USE, AND METHODS OF TREATMENT | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-09-01 | — | — | US | claimed |
| WO-2015066302-A2 | COMPOSITIONS, METHODS OF USE, AND METHODS OF TREATMENT | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2015-05-07 | — | — | WO | claimed |
| US-20110130390-A1 | Use of COX-2 Inhibitors for the Treatment of Schizophrenia, Delusional Disorders, Affective Disorders, Autism or Tic Disorders | MUELLER NORBERT | 2011-06-02 | — | — | US | claimed |
| US-20070142411-A1 | Use of cyclooxygenase-2 selective inhibitors for the treatment of schizophrenic disorders | GLAXO GROUP LIMITED (GB) | 2007-06-21 | — | — | US | claimed |
| US-20060252766-A1 | Methods using a combination of 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia | PFIZER INC | 2006-11-09 | — | — | US | claimed |
| WO-2003088958-A2 | COMBINATIONS OF COX-2 INHIBITORS AND OTHER AGENTS FOR THE TREATMENT OF PARKINSON’S DISEASE | PHARMACIA CORPORATION (US) | 2003-10-30 | — | — | WO | claimed |
| US-20030157061-A1 | Combinations of a cyclooxygenase-2 selective inhibitor and a TNFalpha antagonist and therapeutic uses therefor | PHARMACIA CORPORATION (US) | 2003-08-21 | — | — | US | claimed |
| US-20030130334-A1 | Methods and compositions for the treatment of psychiatric disorders | MULLER NORBERT | 2003-07-10 | — | — | US | claimed |
| US-20030119895-A1 | Methods using a combination of a 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia | PHARMACIA CORPORATION | 2003-06-26 | — | — | US | claimed |
| US-20030114418-A1 | Method for the treatment and prevention of pain and inflammation with glucosamine and a cyclooxygenase-2 selective inhibitor and compositions therefor | PHARMACIA CORPORATION | 2003-06-19 | — | — | US | claimed |
| US-20030114416-A1 | Method and compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate | PHARMACIA CORPORATION | 2003-06-19 | — | — | US | claimed |
| WO-2003015799-A1 | COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF PAIN AND INFLAMMATION WITH A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND CHONDROITIN SULFATE | PHARMACIA CORPORATION (US) | 2003-02-27 | — | — | WO | claimed |
| WO-2003015797-A1 | COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF PAIN AND INFLAMMATION WITH A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND GLUCOSAMINE | PHARMACIA CORPORATION (US) | 2003-02-27 | — | — | WO | claimed |
| US-20030013739-A1 | Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia | PHARMACIA CORPORATION | 2003-01-16 | — | — | US | claimed |
| WO-2002102297-A2 | USE OF COX-2 INHIBITORS FOR THE TREATMENT OF SCHIZOPHRENIA, DELUSIONAL DISORDERS, AFFECTIVE DISORDERS, AUTISM OR TIC DISORDERS | MUELLER NORBERT (DE) | 2002-12-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130334-A1 | Methods and compositions for the treatment of psychiatric disorders | TPH2, MAOB, PTGS2 | CYP19A1 918/4885KMT2A 1559/4885PTGS2 3/4885 |
| US-20110130390-A1 | Use of COX-2 Inhibitors for the Treatment of Schizophrenia, Delusional Disorders, Affective Disorders, Autism or Tic Disorders | PTGES2, PTGER2, PTGDR2 | CYP19A1 2809/4885KMT2A 1078/4885PTGS2 4/4885 |
| US-20030119895-A1 | Methods using a combination of a 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia | PTGS2, PTGES2, PTGS1 | CYP19A1 43/4885KMT2A 1672/4885PTGS2 1/4885 |
| US-20060252766-A1 | Methods using a combination of 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia | PTGS2, PTGES2, PTGES3 | CYP19A1 28/4885KMT2A 1485/4885PTGS2 1/4885 |
| US-20030114416-A1 | Method and compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate | CSGALNACT1, PTGS2, PTGS1 | CYP19A1 2545/4885KMT2A 3701/4885PTGS2 2/4885 |
| US-20030013739-A1 | Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia | PTGS2, PTGES2, PTGS1 | CYP19A1 312/4885KMT2A 1384/4885PTGS2 1/4885 |
| US-20030157061-A1 | Combinations of a cyclooxygenase-2 selective inhibitor and a TNFalpha antagonist and therapeutic uses therefor | TNF, TNFRSF1A, CD40 | CYP19A1 1555/4885KMT2A 4522/4885PTGS2 6/4885 |
| US-20030114418-A1 | Method for the treatment and prevention of pain and inflammation with glucosamine and a cyclooxygenase-2 selective inhibitor and compositions therefor | PTGS2, PTGS1, UGGT1 | CYP19A1 1646/4885KMT2A 4052/4885PTGS2 1/4885 |
| US-20070142411-A1 | Use of cyclooxygenase-2 selective inhibitors for the treatment of schizophrenic disorders | PTGES2, PTGER2, PTGDR2 | CYP19A1 2342/4885KMT2A 1341/4885PTGS2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.